AliveCor

AliveCor is a healthcare technology company that is revolutionizing cardiological care through the use of deep learning. Founded in 2010 and headquartered in the United States, the company's flagship product, the FDA-cleared KardiaMobile device, is the most clinically-validated personal ECG solution globally. With its latest offering, KardiaMobile 6L, AliveCor provides instantaneous detection of various cardiac conditions, including Atrial Fibrillation, Bradycardia, and Tachycardia, through an ECG. The company's use of AI-enabled platform has been pivotal in aiding both patients and clinicians in efficiently detecting atrial fibrillation, a condition linked to a heightened risk of stroke.

Moreover, AliveCor's enterprise platform has allowed third-party providers to manage their patients’ heart conditions using state-of-the-art tools that seamlessly integrate with AliveCor technologies. The company's commitment to data security and compliance is evident through its attainment of ISO 27001 Certification, SOC 2 Type 2 Certification, and HIPAA compliance attestation. The latest Series F investment received by AliveCor on 16 August 2022 saw participation from notable investors such as Khosla Ventures, Qualcomm Ventures, Bold Capital Partners, GE Healthcare, Sweetwater Capital Partners, and WP Global Partners.

AliveCor's dedication to leveraging cutting-edge technology to enhance cardiological care positions it as a pioneering force in the healthcare and information technology industries. As the company continues to make strides in its mission to save lives and transform cardiology, it stands as an intriguing prospect for potential venture capital investment.